(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
02 October 2025 (02.10.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/202455 A2

(51) International Patent Classification:
C12N 15/113 (2010.01)

(21) International Application Number:
PCT/EP2025/058565

(22) International Filing Date:
28 March 2025 (28.03.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/571,886	29 March 2024 (29.03.2024)	US
PCT/EP2024/064367	24 May 2024 (24.05.2024)	EP
2417093.8	20 November 2024 (20.11.2024)	GB

(71) Applicant: **E-THERAPEUTICS PLC** [GB/GB]; 4 Kingdom Street, London W2 6BD (GB).

(72) Inventors: **PURSELL, Natalie Wayne**; c/o e-therapeutics PLC, 4 Kingdom Street, London W2 6BD (GB). **FISCHER, Alexander Wolfgang Christian**; c/o e-therapeutics PLC, 4 Kingdom Street, London W2 6BD (GB). **WHITMORE, Alan Victor**; c/o e-therapeutics PLC, 4 Kingdom Street, London W2 6BD (GB). **MCCARTHY, Amy**; c/o e-therapeutics PLC, 4 Kingdom Street, London W2 6BD (GB). **DE SANTIAGO DOMINGOS DE JESUS, Ines**; c/o e-therapeutics PLC, 4 Kingdom Street, London W2 6BD (GB). **LONGDEN, James**; c/o e-therapeutics PLC, 4 Kingdom Street, London W2 6BD (GB). **DEBACKER, Alexandre**; c/o e-therapeutics PLC, 4 Kingdom Street, London W2 6BD (GB).

(74) Agent: **CMS CAMERON MCKENNA NABARRO OLSWANG LLP**; Cannon Place, 78 Cannon Street, London EC4N 6AF (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
— *with sequence listing part of description (Rule 5.2(a))*

WO 2025/202455 A2

(54) Title: INHIBITORS OF EXPRESSION AND/OR FUNCTION

(57) Abstract: The present invention relates to inhibitors, and compositions containing inhibitors, and uses of the same in the treatment or prevention of a disease, disorder or condition related to HFrEF, such as an ischaemic heart disease, and/or HFpEF.